Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Ligand Pharmaceuticals shares | $133.25

Own Ligand Pharmaceuticals shares in just a few minutes.

Ligand Pharmaceuticals logo

About our promoted products: Our 'promoted' products are presented as a result of a commercial advertising arrangement or to highlight a particular feature. Promoted products are not a recommendation, an indication a product is the best in its category, nor represent all products in the market. It is important to compare your options and find the right product for you. Some of our promoted products are CFD providers. CFDs are complex financial products and traders are at high-risk of losing all of or more than their initial investment

How to buy shares in Ligand Pharmaceuticals from New Zealand

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Ligand Pharmaceuticals Find the stock by name or ticker symbol: LGND. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Ligand Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of $115.39, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Ligand Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Ligand Pharmaceuticals. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Compare trading platforms

Name Product Available Investment Types Min. Monthly Fee Available Markets
OFFER
Hatch
Shares, ETFs
$0
US
Sign up to Hatch through Finder and get a $20 top-up when you deposit $100 or more. Invest in more than 4,100 US companies and exchange-traded funds (ETFs) - no minimum investment or monthly fees.
OFFER
Stake
Shares, ETFs
$0
US
Sign up through Finder and use referral code "FINDERNZ" for a free stock valued up to US$150. Trade more than 4,500 US-listed stocks and ETFs through Stake with $0 fees on trades.
Sharesies
Shares, ETFs, Managed Funds, Index Funds
$0
US, NZ, AU, Funds with exposure to multiple markets
Trade and invest in more than 5,000 companies, ETFs and managed funds across New Zealand, the US and Australia.
loading

Compare up to 4 providers

Important: By investing in a share CFD, you are speculating on the price movement of that share and do not have ownership of the underlying asset. CFDs are complicated financial products are are more suited to experienced trader. Learn more about CFD trading
Name Product Minimum Opening Deposit Minimum Opening Deposit Commission Available Markets Platforms
Plus500 CFD
NZ 200
200
No commission
Indices, FX, Shares, Commodities, Cryptocurrency, ETFs, Options
Plus500 WebTrader
CFD Service. Your capital is at risk.
Trade CFDs on shares, forex, crypto, indices, commodities and more.
BlackBull Markets CFD
USD 200
200
No commission
Indices, FX, Commodities, Precious metals
MetaTrader 4, MetaTrader 5
CFD Service. Your capital is at risk.
Trade CFDs on shares, forex, indices, commodities, precious metals and more.
CMC Markets CFD
NZD 0
0
0.10% with a NZ$ 7 minimum
Indices, FX, Shares, Commodities, Cryptocurrency, ETFs, Precious metals
MetaTrader 4,CMC Next Generation
CFD Service. Your capital is at risk.
Trade CFDs on shares, forex, cryptocurrency, indices, commodities and more.
IG Markets CFDs
AUD 0
0
0.08% with $7 minimum
Indices, FX, Shares, Commodities, Cryptocurrency, Options, ETPs
MetaTrader 4, ProRealTime
CFD Service. Your capital is at risk.
Trade from over 17,000 markets with a leading service for CFD trading and forex.
loading

Compare up to 4 providers

Ligand Pharmaceuticals share price

Use our graph to track the performance of LGND stocks over time.

Ligand Pharmaceuticals shares at a glance

Information last updated 2021-07-02.
OpenUSD135.85
HighUSD135.85
LowUSD133.13
CloseUSD133.25
Previous closeUSD135.93
Change USD-2.68
Change % -1.9716%
Volume 105,475
Information last updated 2021-07-30.
52-week rangeUSD78.26 - USD219.75
50-day moving average USD126.28
200-day moving average USD141.1944
Wall St. target priceUSD213.57
PE ratio 49.5048
Dividend yield N/A (0%)
Earnings per share (TTM) USD2.403

Ligand Pharmaceuticals price performance over time

Historical closes compared with the last close of $133.25

1 week (2021-07-22) N/A
1 month (2021-07-02) 133.25
3 months (2021-04-30) -8.66%
6 months (2021-01-29) N/A
1 year (2020-07-29) N/A
2 years (2019-07-29) N/A
3 years (2018-07-29) N/A
5 years (2016-07-29) N/A

Is Ligand Pharmaceuticals under- or over-valued?

Valuing Ligand Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ligand Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ligand Pharmaceuticals's P/E ratio

Ligand Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 50x. In other words, Ligand Pharmaceuticals shares trade at around 50x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Ligand Pharmaceuticals's PEG ratio

Ligand Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3282. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ligand Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Ligand Pharmaceuticals's EBITDA

Ligand Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$65 million.

The EBITDA is a measure of a Ligand Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Shorting Ligand Pharmaceuticals shares

There are currently 1.8 million Ligand Pharmaceuticals shares held short by investors – that's known as Ligand Pharmaceuticals's "short interest". This figure is 0.3% up from 1.8 million last month.

There are a few different ways that this level of interest in shorting Ligand Pharmaceuticals shares can be evaluated.

Ligand Pharmaceuticals's "short interest ratio" (SIR)

Ligand Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Ligand Pharmaceuticals shares currently shorted divided by the average quantity of Ligand Pharmaceuticals shares traded daily (recently around 166821.34724858). Ligand Pharmaceuticals's SIR currently stands at 10.54. In other words for every 100,000 Ligand Pharmaceuticals shares traded daily on the market, roughly 10540 shares are currently held short.

However Ligand Pharmaceuticals's short interest can also be evaluated against the total number of Ligand Pharmaceuticals shares, or, against the total number of tradable Ligand Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ligand Pharmaceuticals's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Ligand Pharmaceuticals shares in existence, roughly 110 shares are currently held short) or 0.111% of the tradable shares (for every 100,000 tradable Ligand Pharmaceuticals shares, roughly 111 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Ligand Pharmaceuticals.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Go to site